- Home
- ELVN vs SCSC Comparison
ELVN vs SCSC Comparison
Compare ELVN & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SCSC
- Stock Information
- Founded
- ELVN 2016
- SCSC 1992
- Country
- ELVN United States
- SCSC United States
- Employees
- ELVN N/A
- SCSC N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SCSC Retail: Computer Software & Peripheral Equipment
- Sector
- ELVN Health Care
- SCSC Technology
- Exchange
- ELVN Nasdaq
- SCSC Nasdaq
- Market Cap
- ELVN 1.1B
- SCSC 1.1B
- IPO Year
- ELVN 2020
- SCSC 1994
- Fundamental
- Price
- ELVN $22.13
- SCSC $51.00
- Analyst Decision
- ELVN Strong Buy
- SCSC Hold
- Analyst Count
- ELVN 5
- SCSC 1
- Target Price
- ELVN $37.80
- SCSC N/A
- AVG Volume (30 Days)
- ELVN 221.0K
- SCSC 249.9K
- Earning Date
- ELVN 03-13-2025
- SCSC 01-30-2025
- Dividend Yield
- ELVN N/A
- SCSC N/A
- EPS Growth
- ELVN N/A
- SCSC N/A
- EPS
- ELVN N/A
- SCSC 3.14
- Revenue
- ELVN N/A
- SCSC $3,159,084,000.00
- Revenue This Year
- ELVN N/A
- SCSC $2.58
- Revenue Next Year
- ELVN N/A
- SCSC $4.90
- P/E Ratio
- ELVN N/A
- SCSC $16.34
- Revenue Growth
- ELVN N/A
- SCSC N/A
- 52 Week Low
- ELVN $10.90
- SCSC $31.01
- 52 Week High
- ELVN $30.03
- SCSC $53.90
- Technical
- Relative Strength Index (RSI)
- ELVN 46.81
- SCSC 57.25
- Support Level
- ELVN $21.45
- SCSC $49.32
- Resistance Level
- ELVN $22.82
- SCSC $52.06
- Average True Range (ATR)
- ELVN 1.52
- SCSC 1.17
- MACD
- ELVN 0.03
- SCSC 0.41
- Stochastic Oscillator
- ELVN 41.27
- SCSC 77.32
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.